| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.28 | 4e-07 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.24 | 1e-05 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.21 | 5e-05 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 9e-05 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |